As Johnson & Johnson (J&J) tied the bow on its all-cash tender offer takeover of Actelion Ltd. to gain an impressive franchise in pulmonary arterial hypertension (PAH), an expected decision grew near on the device portion of United Therapeutics Corp.’s drug-device combo Remosynch – an implantable pump system for delivery of the PAH drug Remodulin (treprostinil).